Ambu blames hospital staff shortage for European setback
The medtech company’s negative growth in Europe is being worked on, emphasizes the company’s CEO, Britt Meelby Jensen.
For subscribers
Beta Bionics granted FDA approval for bionic pancreas
For subscribers
Coloplast wants data on new ostomy product before deciding market viability
Coloplast CEO Kristian Villumsen says data for ostomy leakage product Heylo is expected to be ready after the summer, with launch still scheduled for 2023.For subscribers
Coloplast grows according to plan, adjusts expectations slightly
However, a currency headwind draws down figures closer to home.For subscribers
Coloplast to compare new single-use catheter with competing product
A new crossover study is meant to determine whether a new catheter from Coloplast is better than US Hollister’s catheter for women.For subscribers
Analyst: Ambu disappoints on key figures despite positive top line
Wednesday’s financial report from Ambu is disappointing in terms of overall results and the bottom line. However, the top line development is positive, is the evaluation from Sydbank analyst.For subscribers
Ambu's revenues and earnings disappoint despite top-line growth
Growth in the second quarter is a little weaker than the consensus estimate, while the Danish medtech company’s profit has seen a sharp year-over-year drop.For subscribers
Analyst sees Ambu endoscope sales as driving growth
Sydbank analyst Søren Løntoft Hansen expects Ambu’s core business, anaesthesia and patient monitoring, to experience a more moderate growth in the coming report for Q2.For subscribers
Ambu finds new COO at biotech firm
Henrik Birk has previously served as chief operating officer at Bavarian Nordic.For subscribers
Coloplast improves pulmonary health in recent study
Coloplast’s new range of heat and moisture exchangers and adhesives, dubbed Provox Life, improves pulmonary health and quality of life for people living with laryngectomy.For subscribers
Mexico plant weighs down Ambu's climate account
Though a newly established plant in Juárez is halting Ambu’s climate efforts, CEO Britt Meelby Jensen won’t resort to buying green certificates there, like it already does in China.For subscribers
Ambu competitor takes the lead in US and UK
While Ambu was busy focusing on its gastroscopy area, US-based Verathon launched a product for airway procedures. ”They’ve got a head start,” says Ambu’s CEO, Britt Meelby Jensen.For subscribers
Coloplast's newest business area could become its biggest
Atos Medical could accelerate growth and, in the long term, become the Danish medtech company’s most important business leg, says the unit’s chief.For subscribers
Ambu relaunches formerly recalled product
Since May of last year, the Danish medtech company has been working on correcting a safety flaw on a key product within its pulmonology suite.For subscribers
Coloplast testing silicone dressing against standard care
In a clinical trial, the Danish medtech company will demonstrate that the Biatain Silicone dressing is better than commonly used wound care products.For subscribers
Former Ambu CEO to spearhead Swiss biotech company
Juan Jose Gonzalez, who was let go from Ambu in May 2022, finds himself another chief executive position.For subscribers
Analyst: Coloplast study attests to Luja as premium product
The Danish medtech company showed up a competitor last week in a study of a new male catheter product.For subscribers
Coloplast challenges its biggest catheter competitor in clinical contest
The Danish medtech company seeks to take market shares from US-based Hollister by comparing respective catheters, hoping to charge a higher price.For subscribers
Ambu wins European approval of two fifth-generation bronchoscopes
With two recent approvals, the Danish medtech company says it now offers a full portfolio of single-use bronchoscopes.For subscribers
Novo Holdings could earn big on acquisition bid for Synlab
With 17% ownership of the laboratory services provider, Novo Holdings would likely make a pretty penny if an acquisition offer is accepted.For subscribers
Nordnet sees reason in Ambu's speedy capital raise
”Ambu should now consider itself as financially free as bird and ready to soar,” assesses a Nordnet analyst.For subscribers
Ambu share offering complete at 4.7% discount
The Danish medtech company has raised DKK 1.1bn.For subscribers
